Aprea Therapeutics (NASDAQ:APRE) Shares Down 2.5% – Should You Sell?

Aprea Therapeutics, Inc. (NASDAQ:APRE) shares dropped 2.5% on Monday . The company traded as low as $2.34 and last traded at $2.34. Approximately 10,321 shares were traded during trading, a decline of 45% from the average daily volume of 18,909 shares. The stock had previously closed at $2.40.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Aprea Therapeutics Stock Performance

The company has a market capitalization of $12.83 million, a PE ratio of -0.84 and a beta of 0.82. The stock’s fifty day simple moving average is $3.26 and its 200-day simple moving average is $3.29.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in shares of Aprea Therapeutics during the 4th quarter worth about $43,000. LPL Financial LLC acquired a new position in Aprea Therapeutics during the fourth quarter worth approximately $53,000. Landscape Capital Management L.L.C. purchased a new position in Aprea Therapeutics during the fourth quarter worth approximately $116,000. Finally, Stonepine Capital Management LLC boosted its holdings in shares of Aprea Therapeutics by 8.8% in the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after purchasing an additional 12,047 shares during the last quarter. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.